Anti-Vascular Endothelial Growth Factor Therapeutics Market to Grow with a CAGR of 2.25% through 2029

Enhanced patient monitoring technologies and Targeted drug delivery methods are factors driving the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market in the forecast period, 2025-2029.

According to TechSci Research report, “Anti-Vascular Endothelial Growth Factor Therapeutics Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029F”, the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market stood at USD 12.38 Billion in 2023 and is anticipated to grow with a CAGR of 2.25% through 2029. The expansion of the anti-Vascular Endothelial Growth Factor (VEGF) therapeutics market is influenced by several factors. There is an increase in the prevalence of ophthalmic disorders such as macular edema, diabetic retinopathy, retinal vein occlusion, and Age-related Macular Degeneration (AMD). This rise is exacerbated by a growing elderly population, which is more prone to developing these conditions.

The demographic trend of aging is expected to further raise the occurrence of ocular conditions in the foreseeable future. The introduction of brolucizumab by Novartis in 2019 heightened competition among existing medications. Brolucizumab offers prolonged efficacy with an initial loading dose administered every 3 months, followed by subsequent doses given every 8 to 12 weeks. Companies are exploring various formulations and drug delivery systems to improve therapy adoption. For instance, F. Hoffmann La Roche Ltd. is advancing the port delivery system-RG6321 (Ranibizumab), currently undergoing phase III clinical trials. This refillable eye implant continuously dispenses a customized formulation of ranibizumab over several months. The growth of the market faces obstacles due to low screening and diagnostic rates for diabetic retinopathy in developing nations. The heightened risk of intraocular injuries associated with anti-VEGF treatments poses challenges as well. The expiration of patents for major blockbuster drugs, known as the patent cliff, is a significant concern in the pharmaceutical sector, often impacting a substantial portion of company revenues.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Anti-Vascular Endothelial Growth Factor Therapeutics Market”

The Global Anti-Vascular Endothelial Growth Factor Therapeutics Market is segmented into product, disease, end users, regional distribution, and company.

Based on disease, Age-related Macular Degeneration have emerged as the dominating segment in the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market during the forecast period. AMD stands as a prominent cause of vision impairment among individuals aged 50 and older. The global aging population has witnessed a notable surge in AMD cases, consequently escalating the demand for effective treatments. This surge has propelled AMD's dominance in the anti-VEGF therapeutics market. The impact of AMD on one's quality of life is profound, given its impact on central vision critical for tasks like reading, driving, and facial recognition. Patients often require continuous treatment to halt vision deterioration and preserve their remaining sight. Anti-VEGF therapies have emerged as the gold standard for treating neovascular or "wet" AMD, further solidifying AMD's market dominance. Extensive investments by pharmaceutical firms and research entities in developing novel anti-VEGF therapies and refining existing treatments for AMD have yielded innovative solutions with enhanced efficacy, durability, and safety profiles. This ongoing research and development effort have bolstered AMD's position in the anti-VEGF therapeutics market.

Based on region, Asia Pacific have emerged as the fastest growing region in the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market in 2023 due to several key factors. The Asia Pacific region is experiencing an uptick in the occurrence of ophthalmic disorders such as macular edema, diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration (AMD). This surge in eye-related ailments is fueling the demand for anti-VEGF therapeutics in the area. Moreover, several countries in the Asia Pacific region are investing in enhancing their healthcare infrastructure, including facilities specialized in ophthalmic care. This expansion of healthcare infrastructure is improving access to tailored treatments, including anti-VEGF therapies, for individuals with ophthalmic disorders. Pharmaceutical companies are intensifying their efforts to establish a foothold in the Asia Pacific region by introducing anti-VEGF therapies and conducting clinical trials to evaluate their effectiveness and safety across diverse patient demographics. These initiatives are contributing to the expansion of the anti-VEGF therapeutics market in the region.

Major companies operating in Global Anti-Vascular Endothelial Growth Factor Therapeutics Market are:

·         F. Hoffmann-La Roche Ltd. 

·         Biogen MA Inc. 

·         Pfizer Inc. 

·         Coherus BioSciences, Inc. 

·         Amgen Inc. 

·         Viatris Inc. 

·         Bausch Health Companies Inc.

·         Novartis AG

·         Regeneron Pharmaceuticals Inc. 

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The future prospects for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics appear promising. Innovations in personalized medicine, targeted drug delivery, and combination therapies are expected to optimize treatment effectiveness while minimizing adverse effects. The introduction of biosimilars has the potential to improve affordability and accessibility. Enhanced patient monitoring technologies will enable real-time tracking and more precise treatment management. Ongoing research efforts will prioritize addressing resistance mechanisms and long-term safety concerns. With an aging population and a rising prevalence of associated diseases, Anti-VEGF therapeutics will remain pivotal in healthcare, evolving to provide more effective, patient-centric, and cost-efficient solutions for various conditions, including eye diseases and various cancers”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Anti-Vascular Endothelial Growth Factor Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Eylea, Lucentis, Beovu), By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration), By End Users (Hospitals & Clinics, Ambulatory Care centers, Others), By Region and Competition, 2019-2029F”, has evaluated the future growth potential of Global Anti-Vascular Endothelial Growth Factor Therapeutics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Anti-Vascular Endothelial Growth Factor Therapeutics Market.

Contact Us-

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

M: +13322586602

Email: [email protected]

Website: www.techsciresearch.com